Keith Eaton

Dr. Keith Eaton


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2012 in Cancers
Verified
Journal Article
Open access
PDF file
CBChristina Baik
Christina Baik
KEKeith Eaton
Keith Eaton
Lung cancer is the leading cause of cancer death in U.S. and represents a major public health burden. Epidemiologic data have suggested that lung cancer in women may possess different biological characteristics compared to men, as evidenced by a higher proportion of never-smokers among women with lung cancer. Emerging data indicate that female hormones such as estrogen and progesterone play a significant role in lung carcinogenesis. It has been reported that estrogen and progesterone receptors are expressed in lung cancer cell lines as well as in patient-derived tumors. Hormone related risk factors such as hormone replacement therapy have been implicated in lung carcinogenesis and several preclinical studies show activity of anti-estrogen therapy in lung cancer. In this review, we summarize the emerging evidence for the role of reproductive hormones in lung cancer and implications for lung cancer therapy.

1 May 2018 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
KEKeith Eaton
Keith Eaton
PRPerrin E. Romine
Perrin E. Romine
GGGary E. Goodman
Gary E. Goodman
MTMark D. Thornquist
Mark D. Thornquist
MBMatt J. Barnett
Matt J. Barnett
EPEffie W. Petersdorf
Effie W. Petersdorf

3 October 2012 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JBJulie E Bauman
Julie E Bauman
KEKeith Eaton
Keith Eaton
SWSarah G Wallace
Sarah G Wallace
LCLaurie L Carr
Laurie L Carr
SLSang-Joon Lee
Sang-Joon Lee
RMRenato G Martins
Renato G Martins
In non-small cell lung cancer (NSCLC), interstitial hypertension is a barrier to chemotherapy delivery, and is mediated by platelet derived growth factor receptor (PDGFR). Antagonizing PDGFR with imatinib may improve intra-tumoral delivery of paclitaxel, increasing response rate (RR).

14 January 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
PRPerrin E. Romine
Perrin E. Romine
RMRenato G. Martins
Renato G. Martins
KEKeith Eaton
Keith Eaton
DWDouglas E. Wood
Douglas E. Wood
FBFatemeh Behnia
Fatemeh Behnia
HVHubert J. Vesselle
Hubert J. Vesselle
Neoadjuvant chemotherapy is effective in improving survival of resectable NSCLC. Based on findings in the adjuvant and metastatic setting, FDG positron emission tomography (PET) scans may offer early prognostic or predictive value after one cycle of induction chemotherapy. In this phase II non-randomized trial, patients with AJCC version 6 stage IB to IIIB operable NSCLC were treated with 3 cycles of cisplatin and pemetrexed neoadjuvant chemotherapy. Patients underwent FDG-PET scanning prior to and 18 to 21 days after the first cycle of chemotherapy. Investigators caring for patients were blinded to results, unless the scans showed evidence of disease progression. FDG-PET response was defined prospectively as a ≥ 20% decrease in the SUV of the primary lesion. Between October 2005 and February 2010, 25 patients enrolled. Fifty two percent were female, 88% white, and median age was 62 years. Histology was divided into adenocarcinoma 66%, not otherwise specified (NOS) 16%, squamous cell 12%, and large cell 4%. Stage distribution was: 16% IB, 4% IIB, and 79% IIIA. Treatment was well tolerated and only one patient had a grade 4 toxicity. The median follow up was 95 months. The 5 year progression free survival (PFS) and overall survival (OS) for the entire population were 54 and 67%, respectively. Eighteen patients had a baseline FDG-PET scan and a repeat scan at day 18–21 available for comparison. Ten patients (56%) were considered metabolic responders on the day 18–21 FDG-PET scan. Responders had a 5 year PFS and OS of 60 and 70%, respectively, while the percentage for non-responders was 63 and 75% (p = 0.96 and 0.85). This phase II trial did not demonstrate that a PET scan after one cycle of chemotherapy can predict survival outcomes of patients with NSCLC treated with neoadjuvant chemotherapy. NCT00227539 registered September 28th, 2005.

20 May 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
KEKeith Eaton
Keith Eaton
BGBernardo H. L. Goulart
Bernardo H. L. Goulart
RSRafael Santana-Davila
Rafael Santana-Davila
LCLaura Quan Man Chow
Laura Quan Man Chow
RWRebecca L. Wood
Rebecca L. Wood
RMRenato G. Martins
Renato G. Martins
6095 Background: Salivary gland cancers (SGC) are rare, biologically and histologically diverse malignancies with no standard of care therapy in the recurrent/metastatic setting. Eribulin is a microtubule inhibitor with established efficacy in previously treated breast cancer. The purpose of this study was to determine the anticancer activity of eribulin in advanced SGC. Methods: In a single center two-stage single arm phase II design, patients with progressive, recurrent and/or metastatic SCG of the head and neck or other sites, with documented disease progression within the past 6 months and not amenable to curative intent therapy were eligible. Any number of prior cytotoxic chemotherapies was allowed. Patients received eribulin 1.4 mg/m2 IV on Days 1 and 8 of a 21-day cycle until disease progression or unacceptable toxicities. Response was assessed by CT imaging every 6 weeks. The primary endpoint was overall response rate by RECIST 1.1. Secondary endpoints were duration of response (DOR), progression free survival (PFS), disease control rate (DCR), and grade > = 3 toxicities. Results: Between May 2012 and August 2015, 29 patients were enrolled. Median age was 63 (range 34-75); 20 (69%) were male. The most common histologies were adenoid cystic (n = 10) and adenocarcinoma (n = 5). Prior radiation was administered in 25 (86%). Number of prior cytotoxic therapies were: 0 (12, 41%), 1 (13, 45%), 3(3, 10%), 5 (1, 3%). Neutropenia was the most common toxicity (Grade 3 (9, 31%), Grade 4 (4, 14%)). Other grade 3 toxicities were: febrile neutropenia, increased QTc, fatigue and peripheral neuropathy in a single patient each. Median follow-up is 2 years, with 5 patients continuing on treatment. The median number of cycles administered was 4 (range 2-28). Response by RECIST criteria was observed in 3/29 (10%) with 2 PR and 1 CR , 20/29 (69%) patients demonstrated a decrement in tumor size at first assessment. Median PFS was 3 months, DCR was 26/29 (90%) and median DOR was 17.2 months. Conclusions: In this phase II trial of eribulin for advanced SGC, we observed response rates similar to those reported to other cytotoxic therapies and superior to those observed in trials of TKIs. Toxicities were similar to those observed in prior trials with eribulin. Clinical trial information: NCT01613768.

1 August 2008 in Current Pain and Headache Reports
Verified
Journal Article
Closed access
PDF file
KEKeith Eaton
Keith Eaton
DFDeborah A. Frieze
Deborah A. Frieze